Tooth Regrowth Nears Human Trials as Toregem Secures Funding

Toregem Biopharma has raised about $5.3 million to accelerate a drug-based approach that inhibits USAG-1, with plans for a Phase 2 trial in Japan to grow teeth from patients’ own tissue. Building on mouse studies and early human safety data, the company targets a potential market around 2030, but experts caution it may be limited to children due to available dental epithelial cells and could risk uncontrolled tooth growth elsewhere; whether it will work in humans remains uncertain.